567 related articles for article (PubMed ID: 22527106)
41. Risk factors for joint symptoms in postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes.
Egawa C; Hirokaga K; Takao S; Yamagami K; Miyashita M; Baba M; Ichii S; Konishi M; Kikawa Y; Minohata J; Okuno T; Miyauchi K; Wakita K; Suwa H; Hashimoto T; Nishino M; Matsumoto T; Hidaka T; Konishi Y; Sakoda Y; Miya A; Mitsunobu M; Nishikawa H; Kono S; Kokufu I; Sakita I; Kitatsuji K; Oh K; Miyoshi Y
Int J Clin Oncol; 2016 Apr; 21(2):262-269. PubMed ID: 26411314
[TBL] [Abstract][Full Text] [Related]
42. Effect of concurrent prescription antiarthralgia pharmacotherapy on persistence to aromatase inhibitors in treatment-naive postmenopausal females.
Hashem MG; Cleary K; Fishman D; Nichols L; Khalid M
Ann Pharmacother; 2013 Jan; 47(1):29-34. PubMed ID: 23324501
[TBL] [Abstract][Full Text] [Related]
43. Interest in Integrative Medicine Among Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study.
Hack CC; Fasching PA; Fehm T; de Waal J; Rezai M; Baier B; Baake G; Kolberg HC; Guggenberger M; Warm M; Harbeck N; Wuerstlein R; Deuker JU; Dall P; Richter B; Wachsmann G; Brucker C; Siebers JW; Fersis N; Kuhn T; Wolf C; Vollert HW; Breitbach GP; Janni W; Landthaler R; Kohls A; Rezek D; Noesslet T; Fischer G; Henschen S; Praetz T; Heyl V; Kühn T; Krauss T; Thomssen C; Hohn A; Tesch H; Mundhenke C; Hein A; Rauh C; Bayer CM; Jacob A; Schmidt K; Belleville E; Hadji P; Brucker SY; Wallwiener D; Kümmel S; Beckmann MW; Paepke D
Integr Cancer Ther; 2017 Jun; 16(2):165-175. PubMed ID: 27627986
[TBL] [Abstract][Full Text] [Related]
44. Incidence and management of arthralgias in breast cancer patients treated with aromatase inhibitors in an outpatient oncology clinic.
Menas P; Merkel D; Hui W; Lawton J; Harper A; Carro G
J Oncol Pharm Pract; 2012 Dec; 18(4):387-93. PubMed ID: 22277833
[TBL] [Abstract][Full Text] [Related]
45. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer.
Partridge AH; LaFountain A; Mayer E; Taylor BS; Winer E; Asnis-Alibozek A
J Clin Oncol; 2008 Feb; 26(4):556-62. PubMed ID: 18180462
[TBL] [Abstract][Full Text] [Related]
46. Patient-reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy.
Kidwell KM; Harte SE; Hayes DF; Storniolo AM; Carpenter J; Flockhart DA; Stearns V; Clauw DJ; Williams DA; Henry NL
Cancer; 2014 Aug; 120(16):2403-11. PubMed ID: 24802413
[TBL] [Abstract][Full Text] [Related]
47. [Quality of life analysis of postmenopausal, early breast cancer patients treated with anastrozole (RADAR-II)].
Horváth Z
Magy Onkol; 2012 Dec; 56(4):242-6. PubMed ID: 23236594
[TBL] [Abstract][Full Text] [Related]
48. Effects of aromatase inhibitors and body mass index on steroid hormone levels in women with early and advanced breast cancer.
Elliott KM; Dent J; Stanczyk FZ; Woodley L; Coombes RC; Purohit A; Palmieri C
Br J Surg; 2014 Jul; 101(8):939-48. PubMed ID: 24687409
[TBL] [Abstract][Full Text] [Related]
49. Reduced breast cancer incidence in women treated with subcutaneous testosterone, or testosterone with anastrozole: a prospective, observational study.
Glaser RL; Dimitrakakis C
Maturitas; 2013 Dec; 76(4):342-9. PubMed ID: 24028858
[TBL] [Abstract][Full Text] [Related]
50. Health-related quality of life of postmenopausal Chinese women with hormone receptor-positive early breast cancer during treatment with adjuvant aromatase inhibitors: a prospective, multicenter, non-interventional study.
Cao A; Zhang J; Liu X; Wu W; Liu Y; Fan Z; Zhang A; Zhou T; Fu P; Wang S; Ouyang Q; Tang J; Jiang H; Zhang X; Pang D; He J; Shi L; Wang X; Sheng Y; Mao D; Shao Z
Health Qual Life Outcomes; 2016 Mar; 14():51. PubMed ID: 27009092
[TBL] [Abstract][Full Text] [Related]
51. Low adherence to upfront and extended adjuvant letrozole therapy among early breast cancer patients in a clinical practice setting.
Lee HS; Lee JY; Ah YM; Kim HS; Im SA; Noh DY; Lee BK
Oncology; 2014; 86(5-6):340-9. PubMed ID: 24925302
[TBL] [Abstract][Full Text] [Related]
52. Influence of patient and tumor characteristics on early therapy persistence with letrozole in postmenopausal women with early breast cancer: results of the prospective Evaluate-TM study with 3941 patients.
Nabieva N; Kellner S; Fehm T; Häberle L; de Waal J; Rezai M; Baier B; Baake G; Kolberg HC; Guggenberger M; Warm M; Harbeck N; Wuerstlein R; Deuker JU; Dall P; Richter B; Wachsmann G; Brucker C; Siebers JW; Fersis N; Kuhn T; Wolf C; Vollert HW; Breitbach GP; Janni W; Landthaler R; Kohls A; Rezek D; Noesselt T; Fischer G; Henschen S; Praetz T; Heyl V; Kühn T; Krauss T; Thomssen C; Hohn A; Tesch H; Mundhenke C; Hein A; Rauh C; Bayer CM; Jacob A; Schmidt K; Belleville E; Brucker SY; Kümmel S; Beckmann MW; Wallwiener D; Hadji P; Fasching PA
Ann Oncol; 2018 Jan; 29(1):186-192. PubMed ID: 29045642
[TBL] [Abstract][Full Text] [Related]
53. Adjuvant aromatase inhibitor options in overweight and obese postmenopausal women with breast cancer.
Chlebowski RT
Breast J; 2013; 19(5):552-4. PubMed ID: 23941577
[No Abstract] [Full Text] [Related]
54. Statin use and breast cancer recurrence in postmenopausal women treated with adjuvant aromatase inhibitors: a Danish population-based cohort study.
Harborg S; Heide-Jørgensen U; Ahern TP; Ewertz M; Cronin-Fenton D; Borgquist S
Breast Cancer Res Treat; 2020 Aug; 183(1):153-160. PubMed ID: 32572715
[TBL] [Abstract][Full Text] [Related]
55. Aromatase inhibitors and calcium absorption in early stage breast cancer.
Tevaarwerk A; Burkard ME; Wisinski KB; Shafer MM; Davis LA; Gogineni J; Crone E; Hansen KE
Breast Cancer Res Treat; 2012 Jul; 134(1):245-51. PubMed ID: 22350731
[TBL] [Abstract][Full Text] [Related]
56. Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study.
Wallwiener M; Nabieva N; Feisst M; Fehm T; de Waal J; Rezai M; Baier B; Baake G; Kolberg HC; Guggenberger M; Warm M; Harbeck N; Wuerstlein R; Deuker JU; Dall P; Richter B; Wachsmann G; Brucker C; Siebers JW; Popovic M; Kuhn T; Wolf C; Vollert HW; Breitbach GP; Janni W; Landthaler R; Kohls A; Rezek D; Noesselt T; Fischer G; Henschen S; Praetz T; Heyl V; Kühn T; Krauss T; Thomssen C; Hohn A; Tesch H; Mundhenke C; Hein A; Rauh C; Bayer CM; Schmidt K; Belleville E; Brucker SY; Hadji P; Beckmann MW; Wallwiener D; Kümmel S; Hartkopf A; Fasching PA
BMC Cancer; 2019 Jun; 19(1):611. PubMed ID: 31227025
[TBL] [Abstract][Full Text] [Related]
57. [Adjuvant endocrine therapy for postmenopausal women].
Watanabe G; Ishida T; Ohuchi N
Nihon Rinsho; 2012 Sep; 70 Suppl 7():636-40. PubMed ID: 23350476
[No Abstract] [Full Text] [Related]
58. Androgens and musculoskeletal symptoms among breast cancer patients on aromatase inhibitor therapy.
Gallicchio L; Macdonald R; Wood B; Rushovich E; Helzlsouer KJ
Breast Cancer Res Treat; 2011 Nov; 130(2):569-77. PubMed ID: 21647676
[TBL] [Abstract][Full Text] [Related]
59. Effect of Aromatase Inhibitor Therapy on Sleep and Activity Patterns in Early-stage Breast Cancer.
Bhave MA; Speth KA; Kidwell KM; Lyden A; Alsamarraie C; Murphy SL; Henry NL
Clin Breast Cancer; 2018 Apr; 18(2):168-174.e2. PubMed ID: 29361424
[TBL] [Abstract][Full Text] [Related]
60. Aromatase inhibitor-induced modulation of breast density: clinical and genetic effects.
Henry NL; Chan HP; Dantzer J; Goswami CP; Li L; Skaar TC; Rae JM; Desta Z; Khouri N; Pinsky R; Oesterreich S; Zhou C; Hadjiiski L; Philips S; Robarge J; Nguyen AT; Storniolo AM; Flockhart DA; Hayes DF; Helvie MA; Stearns V
Br J Cancer; 2013 Oct; 109(9):2331-9. PubMed ID: 24084768
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
